ribavirin has been researched along with Rift Valley Fever in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Donnelly, G; Friedrich, B; Hensley, LE; Keeney, A; Lin, K; Nalca, A; Olinger, G; Reed, C; Shamblin, J; Smith, DR; Wilhelmsen, C | 1 |
| Galimzianov, KhM; Kovalenko, AL; Lokteva, OM; Romantsov, MG; Stepanov, AV | 1 |
| Jones, DE; Peters, CJ; Reynolds, JA; Slone, TW; Stephen, EL | 1 |
| Canonico, PG | 1 |
| Canonico, PG; Kende, M; Levy, HB; Lupton, HW; Rill, WL | 1 |
| Alving, CR; Canonico, PG; Kende, M; Rill, WL; Swartz, GM | 1 |
2 trial(s) available for ribavirin and Rift Valley Fever
| Article | Year |
|---|---|
[Experimental and clinicolaboratory evaluation of complex therapy efficacy in arboviral infections].
Topics: Acridines; Adolescent; Adult; Aged; Animals; Antiviral Agents; Dengue; Encephalomyelitis, Venezuelan Equine; Female; Hemorrhagic Fever, Crimean; Humans; Interferon Inducers; Ixodes; Male; Mice; Middle Aged; Ribavirin; Rift Valley Fever; RNA, Double-Stranded; RNA, Fungal; Tilorone; Young Adult | 2012 |
Efficacy, toxicology and clinical applications of ribavirin against virulent RNA viral infections.
Topics: Administration, Oral; Animals; Arbovirus Infections; Arenaviridae; Arenaviridae Infections; Cattle; Clinical Trials as Topic; Cricetinae; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Encephalitis; Erythrocytes; Hemorrhagic Fever with Renal Syndrome; Hepatitis, Viral, Animal; Humans; Macaca mulatta; Mice; Orthohantavirus; Ribavirin; Ribonucleosides; Rift Valley Fever; Rift Valley fever virus; RNA Viruses; Virus Diseases | 1985 |
4 other study(ies) available for ribavirin and Rift Valley Fever
| Article | Year |
|---|---|
Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development.
Topics: Animals; Antiviral Agents; Disease Models, Animal; Female; Mice; Mice, Inbred BALB C; Peripheral Nervous System Diseases; Ribavirin; Rift Valley Fever; Rift Valley fever virus; Viral Vaccines | 2013 |
Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator.
Topics: Animals; Antiviral Agents; Carboxymethylcellulose Sodium; Cell Line; Cricetinae; Female; Glucans; Humans; Immunization, Passive; Interferon Inducers; Interferons; Macaca mulatta; Macrophage Activation; Male; Mesocricetus; Methylcellulose; Mice; Mice, Inbred Strains; Poly I-C; Polylysine; Ribavirin; Rift Valley Fever; Rift Valley fever virus | 1986 |
Enhanced therapeutic efficacy of poly(ICLC) and ribavirin combinations against Rift Valley fever virus infection in mice.
Topics: Animals; Carboxymethylcellulose Sodium; Drug Administration Schedule; Drug Therapy, Combination; Female; Interferon Inducers; Methylcellulose; Mice; Poly I-C; Polylysine; Ribavirin; Ribonucleosides; Rift Valley Fever | 1987 |
Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice.
Topics: Animals; Female; Injections, Intravenous; Liposomes; Mice; Ribavirin; Ribonucleosides; Rift Valley Fever; Time Factors; Tissue Distribution | 1985 |